AVTO5: Complete Response Letter
A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761461's history or Alvotech USA's company page.
On Nov 26, 2025, FDA declined to approve AVTO5 (BLA 761461) from Alvotech USA Inc. in its present form, citing facility inspections, product quality. openFDA lists it as not yet approved.
- Letter date: Nov 26, 2025
- Application: BLA 761461
- Since then: Not approved
What FDA Cited
FDA's own section headings in the letter; each finds other letters citing itThe Letter
Text from openFDA(1) Following pre-license inspection of oe , listed in this application, FDA conveyed deficiencies to the representative of the facility. The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on the FDA Form 483 p...… openFDA did not return the full text just now. Open it in the letter search.
Alvotech USA's Other Letters
Newest firstRecord
- Company
- Alvotech USA Inc.
- Application
- BLA 761461
- Status in openFDA
- Unapproved
FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters